Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
120 hedge funds and large institutions have $740M invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 49 closing their positions.
688% more call options, than puts
Call options by funds: $31.3M | Put options by funds: $3.97M
13% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 39
15% less funds holding
Funds holding: 141 → 120 (-21)
24% less capital invested
Capital invested by funds: $973M → $740M (-$233M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
43% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 49
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$57M |
| 2 |
VAM
Visium Asset Management
New York
|
+$21.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.7M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$12.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.9M |
Top Sellers
HZNP Hedge Fund Activity: Q3 2014 in Review
120 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2014, worth a combined $740M — down 24% from $973M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of HZNP and 28 opened new positions — a net loss of 21 holders — while 39 trimmed existing stakes and 44 added.
The largest buyer was Deerfield Management, adding an estimated $57M. The largest seller was Essex Woodlands Management, exiting entirely with an estimated $89M sold.
- 120 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2014, down from 141 in Q2 2014.
- Funds reported $740M of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2014, down 24% quarter-over-quarter.
- 28 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2014 and 49 closed out, a net change of -21 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2014 was Deerfield Management, an estimated $57M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2014 was Essex Woodlands Management, an estimated $89M sold.
Based on aggregated 13F filings for Q3 2014.